GSK Pays $321M For Swiss Vaccine Developer Okairos

Law360, New York (May 29, 2013, 2:47 PM EDT) -- GlaxoSmithKline PLC has acquired private Swiss vaccine developer Okairos AG from the company and its venture capital backers for €250 million ($321.4 million) in cash, the U.K. pharmaceutical giant said Wednesday. 

Okairos is a Basel-based drugmaker developing techniques to deliver genetic material to cells to stimulate immune responses that treat cancer and infectious diseases. The acquisition gives GSK a new platform of potential vaccines to complement its existing vaccine department.

GSK now assumes full ownership of Okairos and its early-stage vaccine treatments that could fight a variety...
To view the full article, register now.